The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often underappreciated vulnerability in global pharmaceuticals.
Monica Gorman, PhD
Advertisement
Managing Director, Crowell Global Advisors
Articles by Monica Gorman, PhD
The shifting landscape amid China's biotech rises presents both opportunities and geopolitical challenges for growth strategies.
Welcome to Pharm Exec's new guest column on navigating the geopolitical risks challenging core company strategies in today's shifting global landscape for healthcare.
A proactive strategy that promotes U.S. pharmaceutical manufacturing is a crucial pillar within a resilient and diversified supply chain ecosystem.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
2
Teva Enters $900 Million Agreement to Acquire Emalex
3
Asembia's AXS26 Summit: Q&A with Kim Plesnarski
4
Sanofi Officially Appoints Belén Garijo as Chief Executive Officer Following Shareholder Vote
5